


Colorectal Cancer Drugs Market to hit US\$ 19.96 billion by 2033, (CAGR of 5.2%)

*Colorectal Cancer Drugs Market Outlook
| Market Size, Leading Companies &
Regional Forecasts*


AUSTIN, TX, UNITED STATES, December 2, 2025 /EINPresswire.com/ -- Market Size and Growth

According to DataM Intelligence, the global [colorectal cancer drugs market](#) is expected to increase from USD\$ 12.60 billion in 2024 to USD 19.96 billion by 2033, growing at a compound annual growth rate (CAGR) of 5.2% over the forecast period 2025-2032

In Canada, the average monthly cost for first-line chemotherapy is approximately \$8,992, whereas in the United States, it is higher at around \$11,814.



Cancer Drugs Market



Cancer Drugs Market - By Region

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-

<https://www.datamintelligence.com/download-sample/colorectal-cancer-drugs-market>



United States Colorectal Cancer Drugs Market Report 2024-2033 | Market Share, Competitive Landscape & Innovations"

*DataM Intelligence 4Market
Research LLP*

Key Highlights from the Report

1. North America dominates the Colorectal Cancer Drugs market with a 42.1% share in 2024, fueled by robust healthcare infrastructure, the presence of major pharmaceutical companies such as Pfizer and Bristol-Myers Squibb, and extensive clinical research supported by FDA approvals.

2. Chemotherapy continues to be the primary treatment option, accounting for 57.6% of the

market in 2024, bolstered by FDA-approved protocols and ongoing clinical trials that reinforce its leading position.

3. The intravenous route remains the most widely used mode of administration, expected to grow at a CAGR of 4.5%, due to its ability to deliver comprehensive cancer care, leverage advanced technologies, and provide direct access to branded therapies.

Growth Drivers

- . Increasing incidence of colorectal cancer globally, with over 1.9 million new cases diagnosed in 2024.
- . Advancements in targeted therapies and immunotherapies offering improved patient outcomes and survival rates.
- . Growing adoption of precision medicine approaches enabling tailored treatment regimens.
- . Rising geriatric population, which is more susceptible to colorectal cancer.
- . Government initiatives to improve cancer screening and early diagnosis.
- . Expanding pipeline of novel drugs under clinical trials focusing on better efficacy and fewer side effects.
- . Increased healthcare expenditure in North America, Europe, and Asia-Pacific driving accessibility.

Market Segmentation Analysis

By Drug Type

1. Chemotherapy Agents
2. The traditional backbone of colorectal cancer treatment, holding significant market share but facing competition from newer therapies.

Targeted Therapy Drugs

1. Expected to register the highest CAGR due to increased precision and effectiveness in treating specific genetic mutations such as KRAS, NRAS, and BRAF.

Immunotherapy Drugs

1. Emerging rapidly with promising clinical outcomes, especially in metastatic colorectal cancer cases with microsatellite instability.

Other Drugs

1. Includes hormonal therapies and combination treatments.

By Indication

Metastatic Colorectal Cancer

1. Largest segment due to the high need for effective treatment options for advanced-stage cancer.

Non-Metastatic Colorectal Cancer

1. Growing focus on adjuvant therapies to prevent recurrence post-surgery.

By Route of Administration

Oral Drugs

1. Increasing adoption due to patient convenience and compliance.

Injectables

1. Includes intravenous chemotherapy and monoclonal antibodies.

Request for Customized Sample Report as per Your Business Requirement:

<https://www.datamintelligence.com/customize/colorectal-cancer-drugs-market>

Regional Insights

North America

1. The largest regional market.Strong presence of pharmaceutical companies and advanced healthcare infrastructure.
2. Government initiatives like the U.S. National Cancer Institute's screening programs bolster early detection and treatment.

Europe

1. Growing adoption of biologics and immunotherapies.
2. Markets like Germany, France, and the UK lead in research and reimbursement policies supporting innovative drugs.

Asia-Pacific

1. Fastest-growing market driven by increasing cancer awareness, improving healthcare facilities, and rising disposable incomes.
2. Countries like China, Japan, and India are witnessing rising colorectal cancer incidence and greater adoption of advanced therapies.

Rest of the World

1. Emerging markets in Latin America and Middle East & Africa are gradually increasing access to colorectal cancer treatments due to improved healthcare investments.

Key Players:

The colorectal cancer drugs market is moderately consolidated with key players focusing on product innovation, strategic collaborations, and clinical trials to strengthen their market position.

1. Roche Holding AG
2. Merck & Co., Inc.
3. Bristol-Myers Squibb Company
4. Pfizer Inc.
5. AstraZeneca PLC
6. Novartis AG
7. Amgen Inc.
8. Eli Lilly and Company
9. Bayer
10. Taiho Oncology

Recent Developments:

- Roche launched next-generation targeted therapies with improved efficacy and safety profiles.
- Merck received regulatory approval for its immunotherapy drug for MSI-H colorectal cancer.
- Pfizer and BioNTech are collaborating on mRNA-based colorectal cancer vaccine candidates.
- Amgen expanded its pipeline with biosimilars of key colorectal cancer biologics.
- In February 2025, colorectal cancer, the third most common cancer in the U.S., showed a decline in both incidence and mortality rates. According to the American Cancer Society, colorectal cancer death rates have decreased by 1.2% annually over the past decade, thanks to earlier detection and improved treatments. Many of these advancements were pioneered at Memorial Sloan Kettering Cancer Center, offering hope for continued progress.
- In December 2024, Pfizer received FDA approval for BRAFTOVI, to be used in combination with cetuximab and mFOLFOX6, for the treatment of metastatic colorectal cancer patients with the BRAF V600E mutation, as identified by an FDA-approved test.

Market Outlook and Opportunities

The colorectal cancer drugs market is poised for substantial growth fueled by continued

innovation in molecular diagnostics and personalized treatments. The integration of AI and big data in oncology research is expected to accelerate drug discovery and patient stratification, improving treatment efficacy.

Forecast Highlights:

1. Targeted therapies to capture the largest revenue share by 2032.
2. Immunotherapy drugs are forecasted to grow at the highest CAGR during 2025–2032.
3. Increasing collaboration between pharma and biotech companies to develop combination therapies.
4. Emerging markets in Asia-Pacific offer lucrative growth opportunities due to expanding healthcare access.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): <https://www.datamintelligence.com/buy-now-page?report=colorectal-cancer-drugs-market>

Conclusion

The Global Colorectal Cancer Drugs Market is undergoing rapid transformation with a shift towards precision oncology and immunotherapy, driven by growing patient populations and technological advancements. Industry leaders such as Roche, Merck, and Pfizer are at the forefront of innovation, enabling better patient outcomes and opening new avenues for treatment.

Related Reports

[Global Pediatric Oncology Drugs Market Forecast 2025-2032](#)

[Immuno Oncology Assays Market Analysis and Trends](#)

Sai Kiran

DataM Intelligence 4market Research LLP

+1 877-441-4866

sai.k@datamintelligence.com

Visit us on social media:

[LinkedIn](#)

[X](#)

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.